Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 12, 2012 - Issue 12
Submit an article Journal homepage
47
Views
5
CrossRef citations to date
0
Altmetric
Theme: Bladder Cancer - Review

Emerging personalized approaches for the management of advanced urothelial carcinoma

Che-Kai Tsao Division of Hematology and Medical Oncology, Tisch Cancer Institute, Mount Sinai School of Medicine, NY, USA
,
Benjamin A Gartrell Division of Hematology and Medical Oncology, Tisch Cancer Institute, Mount Sinai School of Medicine, NY, USA
,
William K Oh Division of Hematology and Medical Oncology, Tisch Cancer Institute, Mount Sinai School of Medicine, NY, USA
&
Matthew D Galsky Division of Hematology and Medical Oncology, Tisch Cancer Institute, Mount Sinai School of Medicine, NY, USA. [email protected]
Pages 1537-1543 | Published online: 10 Jan 2014

References

  • Mitra AP, Datar RH, Cote RJ. Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J. Clin. Oncol. 24(35), 5552–5564 (2006).
  • Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH, Zwarthoff EC. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS ONE 5(11), e13821 (2010).
  • Puzio-Kuter AM, Castillo-Martin M, Kinkade CW et al. Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev. 23(6), 675–680 (2009).
  • Stein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol. 19(3), 666–675 (2001).
  • Grossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med. 349(9), 859–866 (2003).
  • Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK; International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group); European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group; Australian Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group; Finnbladder; Norwegian Bladder Cancer Study Group; Club Urologico Espanol de Tratamiento Oncologico Group. International Phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J. Clin. Oncol. 29(16), 2171–2177 (2011).
  • Bochner BH, Kattan MW, Vora KC; International Bladder Cancer Nomogram Consortium. Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J. Clin. Oncol. 24(24), 3967–3972 (2006).
  • Als AB, Dyrskjøt L, von der Maase H et al. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin. Cancer Res. 13(15 Pt 1), 4407–4414 (2007).
  • Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J. Clin. Oncol. 24(5), 778–789 (2006).
  • Mitra AP, Pagliarulo V, Yang D et al. Generation of a concise gene panel for outcome prediction in urinary bladder cancer. J. Clin. Oncol. 27(24), 3929–3937 (2009).
  • Karam JA, Lotan Y, Karakiewicz PI et al. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol. 8(2), 128–136 (2007).
  • Shariat SF, Tokunaga H, Zhou J et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J. Clin. Oncol. 22(6), 1014–1024 (2004).
  • Esrig D, Elmajian D, Groshen S et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N. Engl. J. Med. 331(19), 1259–1264 (1994).
  • Cote RJ, Esrig D, Groshen S, Jones PA, Skinner DG. p53 and treatment of bladder cancer. Nature 385(6612), 123–125 (1997).
  • Stadler WM, Lerner SP, Groshen S et al. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J. Clin. Oncol. 29(25), 3443–3449 (2011).
  • Sternberg CN, Yagoda A, Scher HI et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J. Urol. 133(3), 403–407 (1985).
  • von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, Phase III study. J. Clin. Oncol. 18(17), 3068–3077 (2000).
  • Bellmunt J, Von der Maase H, Mead GM et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy; EORTC30987/Intergroup Study. Proc. Am. Soc. Clin. Oncol. 25, Abstract 5030 (2007).
  • Chow NH, Liu HS, Yang HB, Chan SH, Su IJ. Expression patterns of erbB receptor family in normal urothelium and transitional cell carcinoma. An immunohistochemical study. Virchows Arch. 430(6), 461–466 (1997).
  • Mellon JK, Cook S, Chambers P, Neal DE. Transforming growth factor alpha and epidermal growth factor levels in bladder cancer and their relationship to epidermal growth factor receptor. Br. J. Cancer 73(5), 654–658 (1996).
  • Black PC, Dinney CP. Bladder cancer angiogenesis and metastasis–translation from murine model to clinical trial. Cancer Metastasis Rev. 26(3-4), 623–634 (2007).
  • Wülfing C, Machiels JP, Richel DJ et al. A single-arm, multicenter, open-label Phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer 115(13), 2881–2890 (2009).
  • Galsky MD, Zaks T, Hassani H et al. Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics. Invest. New Drugs 28(2), 194–198 (2010).
  • Galsky MD, Von Hoff DD, Neubauer M et al. Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors. Proceedings of: ASCO Annual Meeting. Orlando, FL, USA, 2009.
  • Milowsky GLC, Shi MM, Urbanowitz G, Zhang Y, Sternberg CN. A multicenter, open-label Phase II trial of dovitinib (TKI258) in advanced urothelial carcinoma patients with either mutated or wild-type FGFR3. Proceedings of: ASCO Annual Meeting. Chicago, IL, USA, 2011.
  • Murray D, Britten RA, Liu D, Tessier A, Hutchison MJ. ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int. J. Cancer 89, 453–457 (2000).
  • Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J. Clin. Invest. 94(2), 703–708 (1994).
  • Rosell R, Lord RVN, Brabender J et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin. Cancer Res. 8, 2286–2291 (2002).
  • Gorlick R, Metzger R, Danenberg KD et al. Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma. J. Clin. Oncol. 16(4), 1465–1469 (1998).
  • Lenz HJ, Shirota Y, Stoehlmacher J et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J. Clin. Oncol. 19, 4298–4304 (2001).
  • Soria JC, Olaussen KA, Dunant A et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N. Engl. J. Med. 355, 983–991 (2006).
  • Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N. Engl. J. Med. 356(8), 800–808 (2007).
  • Reynolds C, Obasaju C, Schell MJ et al. Randomized Phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J. Clin. Oncol. 27(34), 5808–5815 (2009).
  • Bellmunt J, Paz-Ares L, Cuello M et al.; Spanish Oncology Genitourinary Group. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann. Oncol. 18(3), 522–528 (2007).
  • Dimou A, Agarwal S, Anagnostou V et al. Standardization of epidermal growth factor receptor (EGFR) measurement by quantitative immunofluorescence and impact on antibody-based mutation detection in non-small cell lung cancer. Am. J. Pathol. 179(2), 580–589 (2011).
  • Takata R, Katagiri T, Kanehira M et al. Validation study of the prediction system for clinical response of M-VAC neoadjuvant chemotherapy. Cancer Sci. 98(1), 113–117 (2007).
  • Takata R, Katagiri T, Kanehira M et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin. Cancer Res. 11(7), 2625–2636 (2005).
  • Williams PD, Cheon S, Havaleshko DM et al. Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy. Cancer Res. 69(21), 8302–8309 (2009).
  • Maemondo M, Inoue A, Kobayashi K et al.; North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362(25), 2380–2388 (2010).
  • Rosell R, Moran T, Queralt C et al.; Spanish Lung Cancer Group. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 361(10), 958–967 (2009).
  • Sjödahl G, Lauss M, Gudjonsson S et al. A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1. PLoS ONE 6(4), e18583 (2011).
  • Iyer G, Hanrahan AJ, Milowsky MI et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 338(6104), 221 (2012).
  • Shah JB, McConkey DJ, Dinney CP. New strategies in muscle-invasive bladder cancer: on the road to personalized medicine. Clin. Cancer Res. 17(9), 2608–2612 (2011).
  • Pruthi RS, Nielsen M, Heathcote S et al. A Phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results. BJU Int. 106(3), 349–354 (2010).
  • Levitt JM, Yamashita H, Jian W, Lerner SP, Sonpavde G. Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling. Mol. Cancer Ther. 9(5), 1128–1135 (2010).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.